ABSTRACT
The purpose of this study was to evaluate the therapeutic options for diabetes treatment and their potential side effects, in addition to analyzing the risks and benefits of tight glycemic control in patients with diabetic kidney disease. For this review, a search was performed using several pre-defined keyword combinations and their equivalents: “diabetes kidney disease” and “renal failure” in combination with “diabetes treatment” and “oral antidiabetic drugs” or “oral hypoglycemic agents.” The search was performed in PubMed, Endocrine Abstracts and the Cochrane Library from January 1980 up to January 2015. Diabetes treatment in patients with diabetic kidney disease is challenging, in part because of progression of renal failure-related changes in insulin signaling, glucose transport and metabolism, favoring both hyperglycemic peaks and hypoglycemia. Additionally, the decline in renal function impairs the clearance and metabolism of antidiabetic agents and insulin, frequently requiring reassessment of prescriptions. The management of hyperglycemia in patients with diabetic kidney disease is even more difficult, requiring adjustment of antidiabetic agents and insulin doses. The health team responsible for the follow-up of these patients should be vigilant and prepared to make such changes; however, unfortunately, there are few guidelines addressing the nuances of the management of this specific population.
Subject(s)
Humans , Blood Glucose/drug effects , /drug therapy , Diabetic Nephropathies/drug therapy , Hypoglycemic Agents/therapeutic use , Renal Insufficiency, Chronic/drug therapy , Blood Glucose/metabolism , Creatinine/metabolism , Disease Progression , /complications , /metabolism , Diabetic Nephropathies/metabolism , Glomerular Filtration Rate/drug effects , Hypoglycemic Agents/adverse effects , Hypoglycemic Agents/metabolism , Patient Compliance , Renal Insufficiency, Chronic/etiology , Renal Insufficiency, Chronic/metabolismABSTRACT
Mulher de 21 anos apresenta história de 2 anos de irregularidade menstrual, com períodos de amenorréia de até 8 meses e ganho ponderal e há 1 ano galactorréia e cefaléia holocraniana. Exames da ocasião: TSH: 1192 mUI/ml (0,27-4,2); T4T:1,0 mg/dl (4,4-11,4) ; T3T: 0,41 ng/ml (0,7-2,1); prolactina: 69,2 ng/ml (3-20). Em serviço de endocrinologia foi confirmado quadro de mixedema acompanhado de galactorréia. Ressonância magnética (RM) de hipotálamo-hipófise mostrou lesão expansiva intra e supra selar com 1,9 x 1,4 x 1,9 cm nos seus maiores diâmetros, determinando compressão e desvio do quiasma óptico. Diante da possibilidade de hiperplasia das células produtoras de TSH, optamos por iniciar o tratamento do hipotireoidismo com levotiroxina. Após 2 meses de tratamento e normalização dos níveis séricos dos hormônios tireoidianos e do TSH, nova RM mostrou hipófise de tamanho normal. A regressão do volume hipofisário após terapia com levotiroxina confirmou a hipótese diagnóstica de hiperplasia hipofisária decorrente do hipotireoidismo primário. Nossos achados reforçam a importância da avaliação dos hormônios tireoideanos e TSH na investigação de aumento de volume hipofisário prevenindo uma cirurgia desnecessária.